Timber Hill’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

Timber Hill’s Portfolio TLOG Stock Details TLOG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-10,985	Closed	-$46K	–	2831
2014 Q3	$46K	Buy	+10,985	New	+$51.2K	﹤0.01%	2507

Other funds holding TLOG

Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

FWC

First Washington Corp Seattle, Washington $353M AUM 41.46% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Timber Hill's TLOG Position: Q4 2014 in Review

Timber Hill sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q4 2014, closing a stake of 10,985 shares — an estimated $46K sold.

Timber Hill first reported a position in TLOG in Q3 2014 and held it in 1 quarter. The position peaked at $46K in Q3 2014. 31 funds tracked by Wall St. Rank hold TLOG as of Q4 2014.

Timber Hill reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q4 2014 after selling out during the quarter.
Timber Hill sold 10,985 TetraLogic Pharmaceuticals Corporation shares in Q4 2014, an estimated $46K.
Timber Hill first reported a position in TetraLogic Pharmaceuticals Corporation in Q3 2014 and held it in 1 quarter.
Timber Hill's TetraLogic Pharmaceuticals Corporation position peaked at $46K in Q3 2014.
31 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q4 2014.

Based on Timber Hill's 13F filing for Q4 2014, filed 26 Feb 2015.